CK2 targeting potentiates antineoplastic effects of dual HER2/EGFR inhibitor lapatinib and attenuates growth factor-induced epithelial-mesenchymal transition

Submitted by Anonymous on

AbstractBackground CK2 is a pleiotropic, heterotetrameric kinase elevated in numerous cancers and, as such, has garnered much attention as a target for novel antineoplastic agents. Currently, silmitasertib, a selective CK2 inhibitor, has an orphan designation for medulloblastoma and neuroblastoma. Tissue-specific...

Tertiary lymphoid structures in the tumor immune microenvironment of EGFR mutation–positive lung cancer are associated with prognosis: a retrospective review

Submitted by Anonymous on

AbstractBackground The tumor immune microenvironment (TME) of epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC) remains poorly characterized. We hypothesized that a higher abundance of tertiary lymphoid structures (TLSs) is associated with improved disease-free survival (DFS) and that...

Treatment prioritization of chemotherapy-anchored regimens after EGFR-TKI failure in EGFR-mutant NSCLC: a systematic review, pairwise meta-analysis and Bayesian network meta-analysis with probabilistic multi-criteria decision analysis

Submitted by Anonymous on

BackgroundIn advanced EGFR-mutant non–small cell lung cancer (NSCLC) after EGFR-TKI failure, chemotherapy alone offers limited benefit, while heterogeneous e Abstract Background: In advanced EGFR-mutant non–small cell lung cancer (NSCLC) after EGFR-TKI failure, chemotherapy alone offers limited benefit, while heterogeneous efficacy...

Case Report: Diabetic ketoacidosis following EGFR-TKIs therapy via aggravated insulin resistance

Submitted by Anonymous on

ObjectivesEpidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are an established first-line treatment for non-small cell lung cancer (NSC Abstract Objectives: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are an established first-line treatment for non-small cell lung cancer (NSCLC) patients with...

Johnson & Johnson Receives U.S. FDA Priority Review For RYBREVANT FASPRO As Potential First-In-Class EGFR- And MET-Targeted Subcutaneous Treatment For Advanced Head And Neck Cancer

Submitted by Anonymous on

Johnson & Johnson Receives U.S. FDA Priority Review For RYBREVANT FASPRO As Potential First-In-Class EGFR- And MET-Targeted Subcutaneous Treatment For Advanced Head And Neck Cancer Published on 07/30/2026 at 10:21 am EDT S&P Capital IQ Add MarketScreener to your sources...

Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head

Submitted by Anonymous on

Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer PR Newswire RARITAN, N.J., July 30, 2026 Priority Review reinforces the significant potential...

Inhibition of PGC1β-dependent mitochondrial biogenesis enhances EGFR-targeted therapy in lung cancer

Submitted by Anonymous on

Abstract Third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs), including osimertinib, show robust clinical efficacy in EGFR-mutant (EGFRm) non-small cell lung cancer (NSCLC), yet acquired resistance remains inevitable. Here, we demonstrate that osimertinib and other EGFR-TKIs suppress PPARGC1B expression and its regulated...

Subscribe to Newsfeed